Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase 1 Study of C.001 in Retinal Degeneration
Sponsor: Cellio Therapeutics Inc
Summary
This is a first-in-human Phase 1 study evaluating the safety and tolerability of C.001 in patients with retinal diseases involving degeneration of the retinal pigment epithelium. Participants will receive a single administration of C.001 delivered by subretinal injection. The study will evaluate three dose levels in a sequential manner. The primary objective is to assess the safety of C.001 over a 3-month period following administration. Participants will be followed for up to 12 months to further evaluate safety and explore changes in visual function and retinal structure.
Official title: A Phase I Single-Center Open-label Study of C.001 in Patients With Significant Retinal Pigment Epithelium Mediated Maculopathy (RMM)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
15
Start Date
2026-04-07
Completion Date
2029-12-31
Last Updated
2026-08-17
Healthy Volunteers
No
Conditions
Interventions
Injection
C.001 administered once via subretinal injection
Locations (3)
Retina Vision Consultants
Beverly Hills, California, United States
Palo Alto Medical Foundation
Palo Alto, California, United States
Retinal Consultants Medical Group
Sacramento, California, United States